Compared to general population, in the current series we found a higher percentage of Her2 + tumours (24.5% vs 13–15%1) and triple negative tumours (16.3% vs 11.2%17), whereas the incidence of ER/PgR + tumours was similar (77.6% vs 80%). This evidence concerns the gene ERBB2 and neoplasm.